FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Trading Up 2.1 %

Shares of FibroGen stock opened at $0.40 on Friday. The business’s fifty day simple moving average is $0.36 and its 200 day simple moving average is $0.69. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.93. The firm has a market capitalization of $39.84 million, a P/E ratio of -0.32 and a beta of 0.72.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period last year, the firm posted ($0.52) earnings per share. Analysts predict that FibroGen will post -0.86 EPS for the current fiscal year.

Institutional Trading of FibroGen

A number of large investors have recently bought and sold shares of the company. Acadian Asset Management LLC lifted its position in shares of FibroGen by 34.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after buying an additional 860,854 shares during the last quarter. AQR Capital Management LLC lifted its holdings in FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after purchasing an additional 769,586 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in FibroGen during the third quarter worth about $307,000. XTX Topco Ltd bought a new position in FibroGen during the second quarter worth about $424,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of FibroGen by 3,906.9% in the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 280,161 shares in the last quarter. 72.71% of the stock is owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.